Details for Patent: 11,338,011

« Back to Dashboard

Which drugs does patent 11,338,011 protect, and when does it expire?

Patent 11,338,011 protects MYCAPSSA and is included in one NDA.

This patent has twenty-six patent family members in twenty-one countries.

Summary for Patent: 11,338,011

Title:	Method of treating diseases
Abstract:	Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.
Inventor(s):	Roni Mamluk, Sam L. Teichman
Assignee:	Amryt Pharmaceuticals Inc
Application Number:	US17/094,238
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,338,011
Patent Claim Types: see list of patent claims	Use; Composition; Dosage form;

Drugs Protected by US Patent 11,338,011

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Chiesi	MYCAPSSA	octreotide acetate	CAPSULE, DELAYED RELEASE;ORAL	208232-001	Jun 26, 2020		RX	Yes	Yes	11,338,011					USE OF ORAL OCTREOTIDE FOR LONG-TERM MAINTENANCE TREATMENT IN ACROMEGALY PATIENTS WHO HAVE RESPONDED TO AND TOLERATED TREATMENT WITH OCTREOTIDE OR LANREOTIDE

International Family Members for US Patent 11,338,011

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016215350
Australia	2022201269
Australia	2024203939
Canada	2975599